Ronald de Wit - Selected Publications#

1.Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer.
N Eng J Med 2004; 351: 1502-1512.

2. Bellmunt J, Von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester S, de Wit R
Randomized phase Ill study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987.
J Clin On col. 2012 Apr 1;30(10):1107-13. doi: 10.1200/JC0.2011.38.6979. Epub 2012 Feb 27.

3. Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, Maclean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; for the ELM-PC 4 investigators.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Lancet Oncol. 2015 Mar;l 6(3):338-48. doi: 10.1016/Sl 470-2045(15)70027-6. Epub 2015 Feb 18.
PMID: 25701170

4.Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein C, Perini RF, Bajorin DF, MD17 for the KEYNOTE-045 Investigators.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoal 613683. Epub 2017 Feb 17.

5. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisd6ttir A, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
New England Journal of Medicine 2019 Sep 30. doi: 10.1056/NEJMoal 911206.
PMID: 31566937

6. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Flechon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Geczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid 0, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2019 Nov 18. pii: S1470-2045(19)30668-0. doi: 10.1016/S1470-2045(19)30668-0. PMID: 31753727

7. Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N Sternberg, Johann de Bono, Daniel Castellano, Bertrand Tombal, Christian Wulfing, Michael Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Asgerour Sverrisd6ttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Stephane Oudard, Gaetano Facchini, Elizabeth M Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
Lancet Oncol 2020 Nov;21 (11 ):1513-1525. doi: 10.1016/S1470-2045(20)30449-6. Epub 2020 Sep 11.
PMID: 32926841

8. Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nihivr1mr1 H KonPtv RR. Ii H f\l;im K Kr1n;irli;i F. Frpnkl T rlP Wit R
(KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/51470-2045(21 )00147-9. Epub 2021 May 26 PMlD: 34051177

9. Maud Rijnders, Debbie G J Robbrecht, Astrid A M Oostvogels, Mandy van Brakel, Joost L Boormans, Maureen J B Aarts, Hayri E Balcioglu, Paul Hamberg, Jens Voortman, Hans M Westgeest, Martijn P Lolkema, Ronald de Wit, Astrid A M van der Veldt, Reno Debets
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Cancer lmmunol lmmunother. 2022 Aug 17. doi: 10.1007 /s00262-022-03250-0.
PMID : 35976415

10. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Thomas Powles, Elizabeth R Plimack, Dean F Bajorin, Arjun V Balar, Daniel Castellano, Toni K Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I Quinn, Jacqueline Vuky, Nicholas J Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin , Blanca Hornet Moreno, Petros Grivas
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clin Cancer Res . 2022 May 13;28(10}:2050-2060. doi: 10.1158/1078-0432.CCR-21-3089.
PMID: 35247908